Session » Innate Immunity Poster

Date: Sunday, November 10, 2019

Time: 9:00AM-11:00AM

Meeting: 2019 ACR/ARP Annual Meeting

9:00AM-11:00AM: Abstract Number: 30

Aberrant M1 Polarization of Macrophages in Behcet’s Disease

9:00AM-11:00AM: Abstract Number: 32

Aberration of Histone Lysine Methylation in Adult-Onset Still’s Disease Are Novel Biomarker Candidates Associated with the Disease Activity

9:00AM-11:00AM: Abstract Number: 25

Altered Distribution and Enhanced Osteoclastogenesis of Mucosal-associated Invariant T Cells in Gouty Arthritis

9:00AM-11:00AM: Abstract Number: 27

Altered Inflammatory Response of Macrophages in the Fosl-2 Transgenic Mouse Model of Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 22

Beta-2 Glycoprotein I as a DNA- and NET-binding Protein

9:00AM-11:00AM: Abstract Number: 23

Covalent High Molecular Weight HMGB1 Complexes in Muscle Regeneration: Implications in Inflammatory Myopathy

9:00AM-11:00AM: Abstract Number: 33

GS-4875, a First-in-Class TPL2 Inhibitor Suppresses MEK-ERK Inflammatory Signaling and Proinflammatory Cytokine Production in Primary Human Monocytes

9:00AM-11:00AM: Abstract Number: 21

Immuno-Phenotypic Analysis of Peripheral Blood Mononuclear Cells in Rheumatoid Arthritis Patients Treated with E6011, a Humanized Anti-Fractalkine Monoclonal Antibody

9:00AM-11:00AM: Abstract Number: 26

Increased Sodium Accumulation Detected by 23Na-Magnetic Resonance Imaging in Inflamed Knees of Patients with Autoimmune Joint Disease

9:00AM-11:00AM: Abstract Number: 28

Novel Ex Vivo Model of Septic Arthritis Identifies Role of Neutrophils in Joint Destruction

9:00AM-11:00AM: Abstract Number: 31

Regulation of Neutrophil Extracellular Traps by Apremilast (phosphodiesterase 4 Inhibition)

9:00AM-11:00AM: Abstract Number: 24

Role of Trained Immunity in the Pathogenesis of Erdheim-Chester Disease

9:00AM-11:00AM: Abstract Number: 29

Therapeutic Anti-TNF Biologic Agents Exhibit Functional Differences in Blocking TNF-induced Effects on Human Monocytes In Vitro

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].